Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00004836-200607000-00017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Osmotic Demyelination Syndrome in the Setting of Normonatremia: A Case Report and Review of the Literature.
Case Rep Neurol Med
November 2024
Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona, USA.
Osmotic demyelination syndrome (ODS) is a rare complication associated with rapid sodium changes, typically encountered in patients with severe hyponatremia. ODS in patients with normonatremia (ODSIN) is less recognized. We describe a patient with MRI-detected ODSIN following neurotrauma and reviewed the relevant literature.
View Article and Find Full Text PDFCase report: A rare case of delayed drug-induced hyponatremia in recurrent upper tract urothelial carcinoma following GC and Tislelizumab treatment.
Front Oncol
January 2025
The Oncology Department, Shanxi Hospital of Traditional Chinese Medicine, Taiyuan, China.
Drug-induced hyponatremia is an adverse reaction with accelerated electrolyte disturbance. This study reported a rare case of delayed hyponatremia in a 68year-old female with recurrent upper tract urothelial carcinoma after Gemcitabine plus Cisplatin (GC) and Tislelizumab treatment. She had left ureter surgery, recurrence a year later with mildly abnormal kidney function (glomerular filtration rate (GFR) was 54.
View Article and Find Full Text PDFUrine Retention Versus Post-obstructive Diuresis as a Potential Cause of Acute Hyponatremia: A Case Report.
J Community Hosp Intern Med Perspect
January 2025
Critical Care Medicine, Freeman Health System, Joplin, MO, USA.
Acute urine retention is a common urologic emergency that is frequently seen in the Emergency room (ER). Standard treatment includes placing a urinary catheter or a suprapubic catheter with outpatient urologic follow-up. Urine retention can cause complications, such as hyponatremia and post-obstructive diuresis.
View Article and Find Full Text PDFSafety of ceftobiprole in patients with impaired renal, hepatic or immune function: a multinational retrospective hospital chart review (RETRACE study).
Int J Antimicrob Agents
January 2025
Department of Precision Medicine, University of Campania "Luigi Vanvitelli"; Unit of Internal Medicine and Transplants, AORN Ospedali dei Colli, Ospedale V. Monaldi, Piazzale Ettore Ruggieri, 80131, Napoli, Italy. Electronic address:
Ceftobiprole, an advanced-generation cephalosporin with broad bactericidal activity, is approved for community-acquired and hospital-acquired pneumonia (excluding ventilator-associated pneumonia). We aimed to evaluate, in a real-world setting, the safety profile of ceftobiprole in patients with risk conditions (severe renal impairment, hepatic impairment, and immunocompromised status), groups excluded from clinical trials. In this retrospective study (NCT04170309), 396 consecutive charts of patients treated with ceftobiprole during 2016-2022 in 15 centers in France, Italy, and Spain were analyzed: 62 had severe renal impairment, 51 had hepatic impairment, 120 were immunocompromised, and 203 had no predefined risk condition (controls).
View Article and Find Full Text PDFHigh-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial.
Ann Med
December 2025
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Objective: One of the most severe endocrine side effects of immune checkpoint inhibitors (ICI) is hypophysitis leading to adrenal insufficiency. Recovery is rare, although it has been reported after high-dose glucocorticoid treatment. This is the first randomised study to evaluate whether hormonal recovery differs in patients treated with high-dose glucocorticoids versus glucocorticoid replacement therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!